Key facts

Norgine fact sheet

 

We are a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net product sales were EUR 345 million, up 17 per cent.   

We employ over 1,000 people across our commercial, development and manufacturing operations. We manage all aspects of product development, production, marketing, sales and supply. 

Our approach and infrastructure is integrated and focused on ensuring that we win and deliver upon partnership opportunities for growth.

Our locations

 

We are headquartered in the Netherlands.

Overall, we have sites and offices in the UK (Harefield and Hengoed), France (Rueil and Dreux), Germany (Wettenberg), Belgium (Heverlee), The Netherlands (Amsterdam), Nordics (Copenhagen), Switzerland (Luzern), Austria (Vienna), Italy (Milan), Portugal (Lisbon) and Spain (Madrid). Outside Europe, we have offices in Australia (Sydney) and New Zealand.

Our employees

 

We employ over 1,000 employees. We have demonstrated manufacturing, clinical development, medical, pharmacovigilance, regulatory, market access, sales and marketing expertise across Europe, Australia and New Zealand.

 

2017 performance

 

Total net product sales

 

Continues long track record of growth, up 17 per cent.  

Key partnering milestones

 

Partnering is core to our business. Our approach to partnering is flexible which helps to meet the challenges faced by the pharmaceutical sector. We find and work with partners with complementary skills and a shared vision for improving healthcare and the lives of patients and their carers.

  • NORGINE B.V. TO DIVEST ITS CANADIAN ASSETS ACQUIRED THROUGH MERUS LABS INTERNATIONAL INC. TO SEARCHLIGHT PHARMA
    October 2018
  • Norgine B.V. and Shield Therapeutics enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia and New Zealand
    September 2018
  • NEW AND EXCLUSIVE DISTRIBUTION AGREEMENT FOR ENDOCUFF VISIONTM IN EUROPE, MIDDLE EAST AND AFRICA
    September 2018
  • Norgine receives US FDA approval for PLENVU® (NER1006). PLENVU® will be available in the US through Salix in the second half of 2018.
    May 2018
  • Norgine granted rights to AMICUS to commercialise MOVIPREP® in Macedonia and Serbia
    November 2017
  • Norgine expands its partnership with A Pharm s.r.l. to commercialise ZIVEREL® PLUS
    November 2017
  • Norgine B.V. acquires Merus Labs International Inc.
    July 2017
  • Norgine entered into an agreement with Noventure S.L., under which Norgine will distribute GELSECTAN® in Spain, Portugal and Andorra
    March 2017
  • Norgine enters co-promotion agreement with Pfizer in Germany for INFLECTRA® (infliximab) for the treatment of Crohn’s disease and ulcerative colitis
    September 2016
  • Norgine licensed out NER1006 (PLENVU) to Valeant Pharmaceuticals for US and Canada
    August 2016
  • Norgine divests its MENA operations and product rights to Acino
    June 2016
  • Norgine expands its partnership with A Pharm s.r.l. to distribute ZIVEREL® in Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, Norway, Sweden, Switzerland and the UK
    April 2016